Public Health Emergency - Leading a Nation Prepared
In the event of an anthrax attack, antibiotics are the first line of defense for infected individuals. Anthrax and other bacteria can become weaponized or evolve and become resistant to antibiotics. BARDA is working to through public-private partnerships to develop effective antibiotics to treat anthrax infections in the event of an emergency.
BARDA is supporting the following antibiotics:
BARDA is interested in programs to develop and test antibacterial products that are in development to provide post-exposure protection and treatment of one or more of the following biodefense threat agents: anthrax, plague, tularemia, glanders, or melioidosis. To learn more, see the
BARDA Broad Agency Announcement (BAA AOI 3.1).
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language | Vulnerability Disclosure Policy
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages